TrialBlood advances2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
Kirk Cahill et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
TrialBlood advances2025
Kirk Cahill et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.